DARA BioSciences Reports Appointment of Steve Gorlin as a Director and Designation of David J. Drutz as President and Chief Executive Officer
December 20, 2011 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 20, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) reported today that Steve Gorlin has been appointed to fill a vacancy on the Company's Board of Directors. Mr....
DARA BioSciences Reports Management Changes
December 07, 2011 08:45 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Dec. 7, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) reported today that Richard A. Franco, Sr. will retire as Chairman, President and Chief Executive Officer and as a...
Five New U.S. and Foreign Patents Have Been Granted to DARA BioSciences, Inc.
November 08, 2011 08:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 8, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that five new patents were granted in the United States, Asia and Israel for its drug development...
DARA BioSciences Selected to Present at Conferences
November 02, 2011 08:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 2, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that the Company has been selected to present at the following upcoming conferences.
Landmark...
DARA BioSciences Announces Positive Results From a Successfully Completed Phase 1b Clinical Study of DB959 for the Treatment of Type 2 Diabetes
November 01, 2011 08:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Nov. 1, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA), announces the positive results from a successfully completed Phase 1b clinical study for DB959, its peroxisome...
KRN5500 Demonstrated Significant Decrease in the Intensity of Neuropathic Pain in Patients with Cancer, According to Findings Published in the Journal of Pain and Symptom Management
October 10, 2011 10:57 ET
|
DARA BioSciences, Inc.
"A Spicamycin Derivative (KRN5500) Provides Neuropathic Pain Relief in Patients with Advanced Cancer: A Placebo-Controlled, Proof-of-Concept Trial"
RALEIGH, N.C., Oct. 10, 2011 (GLOBE NEWSWIRE) --...
DARA BioSciences Selected to Present the Positive Results of KRN5500 Phase 2 Study at the 5th Annual Therapeutics Summit
September 15, 2011 09:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Sept. 15, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that the Company has been selected to present the positive clinical data results for KRN5500, its...
DARA BioSciences to Present at Rodman & Renshaw Annual Global Healthcare Investment Conference
September 06, 2011 09:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Sept. 6, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that Richard A. Franco, R.Ph., Chief Executive Officer and President, is scheduled to present at...
DARA BioSciences Receives Fast Track Designation From the U.S. FDA for KRN5500 for the Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer
August 18, 2011 09:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Aug. 18, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and...
DARA BioSciences Files Quarterly Report With the SEC and Issues Overview of First Six Months
August 16, 2011 09:00 ET
|
DARA BioSciences, Inc.
RALEIGH, N.C., Aug. 16, 2011 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) a pharmaceutical drug development company, highlights a number of achievements disclosed in the Company's...